CLINICAL CORE

临床核心

• 批准号: 7035626
• 负责人: HARVEY Ira PASS
• 金额: $ 12.47万
• 依托单位: UNIVERSITY OF HAWAII AT MANOA
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-12-01 至 2010-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7035626
• 关键词: asbestos; biomedical facility; cell line; environment related neoplasm /cancer; gene environment interaction; human tissue; lung; mesothelioma; microarray technology; simian virus 40; tissue /cell culture; tissue /cell preparation; tissue resource /registry

The Clinical Core housed at the Karmanos Cancer Institute is intended to be a resource for the program project as a whole and as a valuable source of biological materials necessary for the completion of the individual projects. The Clinical Core will be responsible for the collection, storage, and distribution of mesothelial cells and tissues, and mesothelioma tumors. The functions of the Clinical Core will be to serve as a resource for mesothelioma tumor tissue both snap frozen and paraffin embedded, and as a resource for asbestos-exposed pleura, lung, or peritoneum which is either snap frozen or paraffin embedded. The CORE will also serve as a resource for already established mesothelioma cell lines as well as an ongoing source of cultured human mesothelial cells from patients at the Karmanos Cancer Institute. New mesothelioma cell lines will be started prospectively from mesothleioma patients having resection. The Core will be responsible for the determining the SV40 status on these human mesothelial tissues, mesothelial cells, mesothelioma tumors and cultured mesothelioma cell lines in order to provide the appropriate reagents to the investigators. Tissue arrays for immunohistochemical validation of data will be constructed from paraffin embedded tumors and provided to the individual investigators. The Clinical Core will also coordinate the performance of asbestos lung content analysis from patients with mesothelioma for correlative data in the individual projects. It is estimated that 60-80 new mesothelioma cases per year will be seen at the Karmanos Cancer Institute during the course of the program project, and it is conservatively estimated that 20-30 of these will be accrued as fresh/frozen specimens. Paraffin embedded tumors will be available from all cases. Tumor samples will be used in Projects 1 and 3, and cell lines/cultures will be used in projects 2 and 3. By centralizing these services into a Core, the collection, storage, analysis, and distribution of tissues relevant to mesothelioma carcinogenesis will be better managed and coordinated for the entire Program Project.

卡马诺斯癌症研究所的临床核心旨在成为该计划的资源 项目作为一个整体，并作为完成该项目所需的生物材料的宝贵来源 个人项目。临床核心将负责收集、存储和分发 间皮细胞和组织，以及间皮瘤。临床核心的职能是服务 作为速冻和石蜡包埋的间皮瘤肿瘤组织的资源，以及作为 暴露于石棉的胸膜、肺或腹膜，可速冻或石蜡包埋。核心 还将作为已建立的间皮瘤细胞系的资源以及持续的来源 卡马诺斯癌症研究所培养了来自患者的人类间皮细胞。新间皮瘤细胞 将从接受切除术的间皮瘤患者中前瞻性地开始生产线。核心将负责 用于确定这些人类间皮组织、间皮细胞、间皮瘤的 SV40 状态 肿瘤和培养的间皮瘤细胞系，以便为研究人员提供适当的试剂。 用于数据免疫组织化学验证的组织阵列将从石蜡包埋的肿瘤中构建 并提供给个别调查人员。临床核心还将协调以下方面的绩效： 对间皮瘤患者的石棉肺含量进行分析，以获取各个项目的相关数据。 据估计，卡马诺斯癌症研究所每年会发现 60-80 例间皮瘤新病例 在计划项目实施过程中，保守估计其中 20-30 个将被 作为新鲜/冷冻标本累积。所有病例均可获得石蜡包埋的肿瘤。瘤 样品将用于项目 1 和 3，细胞系/培养物将用于项目 2 和 3。 将这些服务集中到一个核心中，收集、存储、分析和分发与 整个计划项目将更好地管理和协调间皮瘤的致癌作用。